J. Gratama

Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation

C. Lamers, R. Bolhuis, J. Cornelissen, 1999, Bone Marrow Transplantation.

Genetic re-targeting of T lymphocyte specifity

R. Bolhuis, J. Gratama, 1998, Gene Therapy.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

A. Eggermont, P. D. De Mulder, J. Gratama, 1996, British Journal of Cancer.

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

G. Stoter, R. Slingerland, R. Oosterom, 1995, British Journal of Cancer.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

G. Stoter, W. Kruit, J. Gratama, 1996, British Journal of Cancer.